Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GZR18 DDI with Metformin in Overweight/Obese Subjects
NCT06670209Phase 1Not yet recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Peptides
01
Overview
Phase 1, open-label, single-arm trial of bofanglutide in type 2 diabetes mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at Steady State at 24 hours and Area Under the Plasma Concentration-Time Curve Over Dosing Interval at 24 hours. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
bofanglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06670209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670209.